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Background: Atopic dermatitis is a chronic inflammatory skin disease with a high prevalence rate and a large
socioeconomic cost. There are many treatments for atopic dermatitis, such as antihistamine, tacrolimus and
corticosteroids. However, due to concern about the adverse effects, many patients seek alternative treatments. In
this context, natural products are gaining interest. KM110329 is a functional food consisting of four herbs that are
beneficial to skin health. The purpose of this study is to assess the efficacy and safety of KM110329 for atopic
dermatitis.
Methods/design: This study is a randomised, double-blind, placebo-controlled and multicentre trial of KM110329.
For this study, we will recruit 66 atopic dermatitis patients of both sexes, with ages ranging from 18 to 65, from
three university hospitals. The participants will receive either KM110329 or a placebo twice a day for 8 weeks. The
primary end point will be a change in the scoring atopic dermatitis (SCORAD) index. The secondary end points will
include changes to the dermatology life quality index (DLQI) and transepidermal water loss (TEWL), among others.
The outcomes will be measured at every visit. The study will be continued for 8 weeks and will include five visits
with each subject (at screening and at 0, 1, 4 and 8 weeks).
Discussion: This trial will provide research methodologies for evaluate clinical efficacy and safety of KM110329 in
adult patients with atopic dermatitis. In addition, we will evaluate the changes in the general skin health status and
quality of life.
Trial registrations: ClinicalTrials.gov NCT01692093.
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Atopic Dermatitis (AD) is a chronic inflammatory prur-
itic skin disease that is often associated with other atopic
disorders, such as allergic rhinitis and asthma [1]. AD is
characterised by poorly defined erythema with oedema,
vesiculation, weeping in the acute stage, and skin thick-
ening (lichenification) in the chronic stage [2].* Correspondence: epiko@khu.ac.kr
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stated.The prevalence of AD has risen substantially in many
countries in recent decades. AD not only leads to a low
quality of life, but it also causes depression. AD affects
the patients as well as their parents and other family
members as well [3]. Therefore, the socioeconomic cost
of AD is increasing. In Korea, the total number of
people who visit the hospital for AD is 1,035,680 (57th of
total 500 disease), and the total was 62,381,288,330 Won
in 2010. In addition to the medical market for AD
treatments, there is also an enormous cosmetic market
totalling approximately 100 billion Won.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Figure 1 Study flow chart.
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corticosteroids, emollients, topical tacrolimus, topical 1%
pimecrolimus, oral antihistamines, refined-coal tar, topical
doxepin and oral corticosteroids. However, these treat-
ments can cause adverse reactions, such as stinging,
burning, drowsiness, itching, dyspepsia and hypertension.
Therefore, a demand for novel treatments exists, and
functional foods made from natural products have
received considerable attention due to the perception
that they have no adverse effects [2].
KM110329 is compound found in Rubi Fructus,
Houttuyniae Herba, Rehmanniae Radix, and Betulae
Platyphyllae Cortex.
According to herbology textbooks and the World
Health Organization (WHO) glossary, the Korean medi-
cinal efficacies of each component of KM110329 are as
follows [4,5].
The effects of Rubi Fructus are to tonify the kidney, to
secure its essence and to reduce urination. Rubi Fructus
works as a treatment for insufficient consolidation due
to kidney deficiency, and it also has beneficial effects on
the skin.
Houttuyniae Herba has the function of clearing away
heat, detoxifying the body, dissolving boils and draining
pus. As a home remedy, it is used to treat furuncle.
Rehmanniae Radix clears heat, engenders fluid, cools
the blood to stop bleeding and treats agitation, thirst
and skin irritation caused by heat.
Betulae Platyphyllae Cortex mitigates pruritus and skin
pain by clearing heat, draining dampness, dispelling
phlegm and suppressing cough, dispersing swelling, and
detoxifying the body.
Some studies have reported the components of
KM110329 have effect on atopic dermatitis. Recent stud-
ies suggests that Rubi fructus regulates anaphylaxis and
have anti-inflammatory effect [6,7]. Rehmanniae Radix
prevents skin allergic reaction and treats allergen-
induced atopic dermatitis in mice by suppressing the
expression of cytokines, chemokines and adhesion mole-
cules [8,9]. Houttuyniae Herba suppresses Th2 immune
response and regulates inflammatory process [10,11].
Betulae Platyphyllae Cortex inhibits the development of
atopic dermatitis-like skin lesions in NC/Nga mice
through the suppression of the Th2 cell response. It also
attenuates mast cell-mediated allergic inflammation
in vivo and in vitro [12,13].
The aim of the present study is to determine the
clinical efficacy and safety of KM110329 for AD.
We will conduct a randomised, double-blind, placebo-
controlled, multicentre trial of KM110329 in adult
patients with AD. Because of the absence of a gold
standard for the treatment of AD, this trial will be con-
ducted to determine the effectiveness of this functional
food in comparison with a placebo-controlled group.Methods/design
A randomised, double blind, placebo-controlled, multi-
centre trial will be conducted at the Seoul St. Mary’s
Hospital, Chung-ang University Hospital, and Kyung
Hee University Hospital in Gangdong. Participants ful-
filling the eligibility criteria will be selected. The
enrolled participants will be randomly allocated to two
parallel groups corresponding to the KM110329 and
placebo arms. Each participant will be examined for
signs and symptoms of AD before and after taking the
functional food. Figure 1 shows the schematic flow of
the study.
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Subjects will be recruited through three routes. Patients
who visit the trial hospitals and meet the criteria will be
recommended by the physician in charge. Patients who
see the trial poster on bulletin boards or advertisements
in newspapers will visit the trial site voluntarily.
Inclusion criteria and exclusion criteria
The inclusion and exclusion criteria are shown in Inclu-
sion and exclusion criteria section.
Inclusion and exclusion criteria
Inclusion criteria
1. Men and women ages 18 to 65 years
2. Individuals diagnosed with atopic dermatitis
according to the criteria of Hanifin and Rajka
3. Individuals with mild to moderate atopic dermatitis
(objective SCORAD ≤ 40)
4. Written informed consent for participation in the trial
Exclusion Criteria
1. Severe skin disease other than atopic dermatitis
2. Secondary infection with bacteria, fungi, or virus
3. Uncontrolled hypertension (SBP > 145 mmHg or
DBP > 95 mmHg)
4. Severe liver disability (2.5-fold the normal high
range value for ALT, AST)
5. Severe renal disability (sCr > 2.0 mg/dl)
6. Women who are pregnant, lactating, planning a
pregnancy or women of child-bearing age who do
not agree to use proper contraception
7. Use of oral steroids, oral antibiotic or other
immunosuppressants within the past 4 weeks
8. Treated by systemic photochemotherapy within the
past 4 weeks
9. History of drug abuse
10. Hypersensitivity to Rubi Fructus, Houttuyniae
Herba, Rehmanniae Radix, or Betulae Platyphyllae
Cortex
11. Use of other investigational products within the
past two months
Subject withdrawal criteria
The subjects who meet the criteria listed in Subject with-
drawal criteria section will be discontinued from treatment.
The participants who are withdrawn after randomisation
will be followed for outcomes.
Subject withdrawal criteria
1. Use of any forbidden medication or treatment
during the trial that could affect the study result2. Subject’s withdrawal of consent
3. Occurrence of a serious adverse event
4. Detection of eligibility violations, occurrence of
other significant protocol violations during the trial
5. Investigator’s decision to terminate the process for
the sake of the subject’s health
Sample size
Sample size calculations were performed to determine
the number of participants needed to detect the effect
sizes. We obtained an effect size from the previous study
and based on the agreement of experts [14]. The results
from the previous study were used to calculate the
standard deviation [15]. The mean difference and stand-
ard deviation of the scoring atopic dermatitis (SCORAD)
index were 10 and 13.576, respectively. The following
formula was used to estimate the sample size.




¼ 2 1:96þ 0:84ð Þ
2  13:5762
102¼ 28:932
The calculation was performed using 80% power, a 5%
significance level, and a 10% dropout rate. The required
sample size is approximately 33 participants for each
group. Therefore, a total of 66 participants are needed
for this trial.
Randomisation and allocation
The study subjects who satisfy the eligibility criteria
will be randomised using a computer program at an
independent centre (Kyung Hee University Center for
Clinical Research and Drug Development; KCRD). Block
randomisation with block size of 4 will be performed.
The study subjects will be assigned to one of two groups
with a 1:1 allocation ratio by investigator in each study
site. Random numbers will be sent to each centre, and a
randomisation table will be maintained by KCRD during
the research period. Opaque sealed envelopes containing
serial numbers will be delivered to each centre. The ran-
domisation table kept in an opaque sealed envelope by
the contract research organisation (CRO; KCRD) should
be opened according to Standard Operating Procedures
(SOPs).
Blinding
Both the investigator and the subject will be blinded re-
garding the assignment of the study drugs. The CRO of
the sponsor will label the investigational drugs using the
randomisation code number. The labelled experimental
products will be provided to the trial sites by the CRO.
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The participants will receive KM110329 or a placebo
drug for eight weeks. They will take 2 tablets by mouth
with water twice a day after meals.
Interventions
Hanpoong Pharm and Foods Co., Ltd. produced the
KM110329 and the placebo according to Korea Good
Manufacturing Practice (KGMP) standards. KM110329
is a brown-coloured, round-shaped tablet. It is com-
pound of Rubi Fructus, Houttuyniae Herba, Rehmanniae
Radix, and Betulae Platyphyllae Cortex. The placebo
medicine is made of lactose, corn starch and food col-
ouring, and it has a similar appearance, shape, weight,
taste and colour as KM110329.
Primary outcome measurement
The primary outcome in the present study is the change
in the SCORAD index between the baseline (Visit 2)
and after the treatment (Visit 5). The SCORAD index is
a clinical tool for assessing the severity of atopic derma-
titis as objectively as possible. The SCORAD index will
be measured at every visit.
Secondary outcome measurement
Secondary outcome measurements include the change
in the Dermatology Life Quality Index (DLQI), the total
IgE level, eosinophil counts, IL-4, IL-5, IL-13, TEWL





Demographic characteristic eristic √
SCORAD index √
Dermatology Life Quality Index
KiFDA-HM-AD
Laboratory tests1 √
Test for chronic hepatitis2 √
Drug use history √
Concomitant medication √
Pregnancy test √
Medical/drug use history √
Adverse event
Compliance calculation
Inclusion/exclusion criteria check √
Randomisation
1CBC (RBC, Hb, Hct, WBC, Platelet, ESR), Immunological tests (Eosinophil, IgE, IL-4, IL
2Anti-HBs, HBsAg.corneum, and KiFDA-HM-AD. The study schedule is
detailed in Table 1.
Safety outcomes
All variables related to the safety assessment, such as
vital signs, physical examinations, laboratory tests
(complete blood cell count, liver function test, renal
function test) and adverse events (AEs) will be docu-
mented on the case report form (CRF) at every visit.
Statistical analysis
Efficacy assessment
Statistical analyses will be performed for both the ITT
(intention-to treat, all randomly assigned participants)
and PP (per-protocol, participants completed the trial
without any protocol deviations) data sets. The missing
values will be imputed by the last observation carried
forward (LOCF) method. The continuous variables will
be displayed as the mean ± SD(standard deviation), and
the categorical variables will be displayed as the n (%).
The baseline characteristics will be compared by either a
Student’s t-test for continuous variables or the χ2 test
(Fisher’s exact test will be used when the expected value
is < 5) for the categorical data. Alternatively, McNemar’s
test will be used if the normality assumption is not satis-
fied for the continuous variables. For the primary out-
come measures, the mean differences from the baseline
values to the end of treatment will be compared using
an independent T-test.Treatment period
Visit 2 Visit 3 Visit 4 Visit 5
(D 0) (D 7) (D 28) (D 56)
√ √ √ √
√ √ √ √
√ √ √ √
√ √
√ √ √ √
√ √ √ √




-5, IL-13), Liver function tests (AST, ALT), Renal function tests (BUN, Creatinine).
Cheon et al. BMC Complementary and Alternative Medicine 2013, 13:335 Page 5 of 6
http://www.biomedcentral.com/1472-6882/13/335Safety assessment
All participants will report any adverse events that they
experience while undergoing the intervention at every
visit. Every adverse event will be described in the CRF. If
the adverse event is severe and associated with the trial,
the participant will be withdrawn from the trial, and the
appropriate treatment will be given to him or her. For
the safety assessment, a liver function test, blood cell
count test and physical examination will be performed
at Visits 1, 2 and 5. The safety-related variables will be
analysed using the ITT method.
Data and safety monitoring
To maintain the quality of this trial, monitoring will be
conducted by Kyung Hee University Center for Clinical
Research and Drug Development (KCRD; the CRO).
Every institution participating in the trial will be moni-
tored while this trial is in progress using standard
operating procedures.
Ethics
The present study has been approved by the institutional
review boards (IRBs) at each of the three institutions,
which are the Catholic University of Korea Seoul St Mary’s
Hospital (reference KC12HNME0047), the Chung-ang
University Hospital (reference C2011197), and the Kyung
Hee University Hospital at Gangdong (reference KHNMC-
OH-IRB 2011–019). Written informed consent will be
obtained from each participant prior to enrolment. The
trial will be performed in compliance with the Helsinki
Declaration and according to Good Clinical Practice as
described by the Korea Food & Drug Administration.
Discussion
The present study seeks to investigate the clinical
efficacy and safety of KM110329 for AD.
The desire for well-being and to improve one’s quality
of life motivates consumers to purchase functional
foods, thus opening an enormous new market.
The functional food market in Korea was introduced in
the 1990s. It underwent the early stages of growth from
2002 to 2005, and it reached maturity in late 2006, valued
at more than 1,280 billion Won. In the USA, the functional
food market grows more than 6% annually, and it was
estimated to reach 22.5 billion dollars in 2006 [16].
Despite the recent demand for functional food, there
are only a few trial protocols to determine the clinical
efficacy and safety of functional foods. In the present
study, we will evaluate the efficacy of KM110329, a func-
tional food consisting of four herbs that have been
shown to be beneficial for skin health.
A study protocol for the treatment of AD using the
herbal medicine Hwangryunhaedoktang has already been
published [17], however, the present study has severaldistinctive features. First, this will be the first trial to
investigate the efficacy of the functional food KM110329
for the treatment of AD. In the present study, we will
assess not only the usual outcome measurements, such
as SCORAD, DLQI, and IgE, but also TEWL and hydra-
tion in the stratum corneum to assess the overall health
status of the skin.
Second, to the best of our knowledge, this will be the
first trial protocol using KiFDA-HM-AD to evaluate
severity of AD. KiFDA-HM-AD is an evaluation endpoint
for clinical trials of herbal medicinal products related to
AD [18]. The Korea Food and Drug Administration
(KFDA) developed and deployed this assessment tool. This
trial may provide a basic assessment of the reliability and
validity of KiFDA-HM-AD by comparing the outcomes of
the KiFDA-HM-AD with those of the SCORAD and
DLQI.
We hope that this trial protocol will be a reference for
designing further clinical trials for functional foods to
improve skin health.
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